Ed Koval

Chief Business Officer

With more than 25 years of strategy, business / corporate development, alliance management and finance experience in biotech and big-pharma, Ed Koval’s career has focused on the creation of new companies and the strengthening of platforms and pipelines of established ones through financings and strategic partnering deals.

After helping drive the major transactions that led to the founding of ZebiAI, Ed joined the company in June 2020.  Prior to that Ed held senior roles at X-Chem, Novartis, Chiron, Merck, Veloxis and various other biotech companies.

Ed holds B.S. and M.S. degrees in engineering from NYU and RPI as well as an M.B.A from the MIT Sloan School of Management.

Other Team Members

Rafael Gomez-Bombarelli, Ph.D.

Chief Learning Officer

John Cuozzo Ph.D

SVP and Head of Drug Discovery

Richard Wagner, Ph.D.

Founder and Director

Christelle Huguet, Ph.D.

Chair, Scientific Advisory Board

Brant Binder

President
Brian-Goldman

Brian Goldman, Ph.D.

SVP and Chief Computation Scientist

Ed Koval

Chief Business Officer